Thursday Sep 09

Bowel Cancer is One of the Commonest Cancers

Cancers are amongst the commonest causes of death in the United Kingdom, accounting for about one in every four deaths - over 130,000 per annum.  The majority of cancer deaths are from tumours found in four principal sites: lung, bowel, breast and prostate.

Colorectal cancer is the second most common cause of death from cancer in the Western world.  In 1985, there was estimated to be 677,500 new cases and 394,100 deaths worldwide.  In the United Kingdom there is approximately a 4% lifetime risk, 35,000 new cases annually and 17,000 deaths.

Colorectal Polyp (Adenoma)

There is very good evidence to suggest that almost all cancers start off as a polyp.  These grow over a reasonable length of time from just a tiny colony of abnormal cells.  As they grow then the cells become increasingly abnormal and the usual restrictions on cell growth are lost.  This means that growth accelerates and once the cells start to invade through the lining of the bowel wall then an invasive cancer is formed.

Screening is the process by which a disease is detected at an early stage whereupon intervention is possible that improves the outcome.

Bowel cancer is an ideal disease for screening which is why the National Health Service has introduced The National Bowel Cancer Creening Programme.

Why Screen for Bowel Cancer?

Regular bowel cancer screening has been shown to reduce the risk of dying from bowel cancer by 16 per cent

But isn't there a National Screening Programme?

There is a National Screening Programme being introduced by the National Health Service that aims to offer screening every two years to all men and women aged 60 to 69.  This will take time to introduce and therefore will not be available immediately to everyone who may wish to be screened.  People aged 70 and over may "request a screening kit by calling a freephone helpline when the programme reaches their area".  If you are under the age of 60 then screening is currently NOT AVAILABLE on the NHS.

 

 

Colorectal cancer and screening



 

1.d.i. Rationale for screening for colorectal cancer

 

In common with other cancers such as breast and cervix, colorectal cancer is suited to the institution of a screening programme:

ยท         it is a major health problem (1.b.i. Demographics)

ยท         there is a lengthy precancerous stage i.e. the adenomatous polyp.

ยท         intervention at an earlier stage affects morbidity and mortality.

ยท         modalities are available to detect polyps.

ยท         the cost of screening is not prohibitive

 

 

1.d.ii. Screening methods for colorectal cancers and adenomas

 

At least 75% of colorectal cancers arise in persons who have no known family history.  As such the screening of high risk families, while potentially valuable to the individuals, is unlikely to have a major impact on the overall incidence or mortality.  Therefore, population based screening is recommended as the way forward.

 

There are several methods by which the population might be screened:

ยท         Symptom questionnaire

ยท         Faecal Occult Blood Testing (FOBT)

ยท         Barium enema

ยท         Colonoscopy

ยท         Flexible sigmoidoscopy

ยท         New advances e.g. K-ras stool testing

 

Symptom Questionnaire

Bowel symptoms are very common and can be an indicator of many general medical conditions (e.g. thyrotoxicosis), large bowel pathology (e.g. colitis) or functional bowel disorders (e.g. irritable bowel syndrome).  As such, one cannot define a high risk group for further intervention through symptomatology alone and the addition of a symptom questionnaire to other screening modalities increases costs with little return.

 

Faecal Occult Blood Testing (FOBT)

FOBT is mainly aimed at the detection of early asymptomatic cancers.  The premise is that such cancers bleed and the detection of these small amounts of blood define a high risk group who undergo further intervention (colonoscopy).  The main advantages of FOBT screening is that it is non-invasive, easily performed without the need for bowel preparation, can be performed on transported specimens and of low cost.  The main disadvantages, however, are low sensitivity, because 40% of cancers and 80% of adenomas are missed by the test, and the late stage in the disease at which lesions bleed, leading to a short lead-time and a requirement for frequent testing.

 

Barium Enema

Traditionally before the advent of fibre-optic technology, imaging of the colon was performed using a barium enema.  It has been shown however that the sensitivity for even quite large colonic lesions can be quite low and the examination requires full bowel preparation and is poorly accepted by patients.

 

Colonoscopy

Initially, colonoscopy may appear to be the best method for screening for colorectal adenomas and cancers.  The sensitivity for even small polyps as small as 5mm is high so that neoplasia is detected at an early stage.  Also, lesions can be removed at the time of screening so colonoscopy can be both diagnostic and therapeutic. 

 

There are however disadvantages to colonoscopic screening:

ยท         full bowel preparation is required.  This normally involves stimulant or osmotic laxatives (e.g. Picolax or Klean prep).  Recommendations include a low fibre diet for several days prior to commencement of preparation which itself starts the day before the examination.

ยท         the majority of colonoscopic examinations are carried out with sedation.  This excludes the subject from driving to and from the hospital, prevents the adequate discussion of results on the day and can be distressing both from the anxiety of not being fully conscious but also the hangover effects that are reported.

ยท         complication rates including perforation are reported as being approximately 1 in 2,000 and a mortality of 1 in 5,000.  Though this may be acceptable in clinical practice in symptomatic patients, it would represent an obstacle to the acceptance of the population to be screened.

ยท         the overall compliance is lower or comparable to flexible sigmoidoscopic screening.

ยท         colonoscopy requires considerable training, skill and experience.  At present, as colonoscopy becomes the investigation of choice for colonic disorders over barium enema, there is a relative shortage of colonoscopists.  A trend that seems set to continue and would increase in magnitude should screening be introduced.

ยท         colonoscopy is the most expensive of the potential screening tools.

 

Flexible Sigmoidoscopy

Flexible sigmoidoscopy has advantages over colonoscopy in that:

ยท         bowel preparation can be undertaken with a phosphate enema that gives good results, is quick and easy to be self-administered at home and is acceptable.

ยท         sedation is not normally required

ยท         there is a very low complication rate including perforation

ยท         it is associated with 70% acceptance rate

ยท         it can be performed by non-medical personnel thus reducing the logistic problem of requiring more endoscopists

ยท         it is relatively cheap

 

However, flexible sigmoidoscopy does not allow visualisation of the proximal bowel.  A 60cm sigmoidoscope, however, can be passed in most cases to the junction of the sigmoid and descending colon below which 60% of colorectal cancers are located.

 

New Advances

Screening for stool markers that are more accurate than occult blood would substantially improve sensitivity.  There is great interest in looking for the DNA alterations that occur in the formation of polyps and cancers in cells exfoliated from neoplasms.  Early investigations targeting single mutations, usually K-ras that is present in less than half of all colorectal neoplasms, show that mutations in tumour can be detected in stools from the same patients.  Colorectal neoplasms however are genetically heterogeneous and no one mutation has been found to be universally expressed.  It is likely that an approach of investigating multiple mutations commonly expressed would improve diagnostic yield.  Ahlquist et al. demonstrated  sensitivities of 91% for colorectal cancer and 82% for adenomas >1cm using a multi-target assay that assessed 15 mutations commonly seen in colorectal neoplasia.

 

Other UK Surgeon Websites

Disclaimer

The Bowel Cancer Screening website is designed to give information on bowel cancer and screening.  Every effort is made to ensure that all information is current but no responsibility can be accepted for out of date or inaccurate information.  Information or advice on this website is no substitute for seeing your doctor.